Pharmafile Logo

Portfolio analysis: Making Go/No-Go decisions to optimise the portfolio

Tuesday 20th March 2018 11:00 EST / 16:00 GMT / 17:00 CEST

Register now: http://bit.ly/2FnXsFx

When a pharma company is either considering acquiring a new agent, or developing one in-house, marketers need to understand the impact on the overall portfolio and decide whether to make a go or no-go decision on that asset.Join US Directors Tom Nolte and Melinda Shorr for this webinar which shows you how market research insights allow you to make confident go/no-go decisions in portfolio planning.

They will address:

Why portfolios need to adapt and change
Success today is not necessarily success tomorrow. Depth and diversification are essential to a strong portfolio – we explore the reasons why you need to actively plan for the future.

Considerations for Go/No-go research design for portfolio planning
We show you how to create an effective market research programme – what stakeholders needs to be involved in the planning process, what questions need to be asked and what methods can be used.

Determining value and magnitude metrics
We discuss the criteria by which additions to a pipeline fit into the key metrics – what value they bring to the portfolio and the size of that opportunity (magnitude). Conversely we will look at what the removal of an asset has on the overall portfolio.

Speed of decision-making
If agents are being developed in-house, evaluations can be made slowly and rigorously. When agents are being acquired, the decision to go or no-go often needs to be made quickly. We discuss the impact on market research design. 
Our presenters will also use a case study to demonstrate how market research insights support better decision-making on new agents in a portfolio.

Question and answer session
Following the presentation there will be a live Q&A where they will address any specific challenges you have encountered or concerns you may have about conducting portfolio analysis studies. We welcome you to submit your questions in advance when you register.

Register now: http://bit.ly/2FnXsFx

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Oncology experience & expertise

Did you know 25% of our business is in Oncology?

First, we need to talk: mental healthcare in the MENA region

In our final installment of articles exploring mental health in emerging markets, we take an in-depth look at the situation in the MENA region

Atopic Dermatitis — Going Beyond the Pill

Published in Pharma Exec April 2018 by Mariel Metcalfe

ESOMAR Asia Pacific 2018

13-15 May, Bangkok

Intellus Worldwide Summit 2018

Visit us on stand number 413

How buyer insights supported the development of an effective market strategy

Our client was developing a new product for HIV and needed to understand buyer willingness to pay in the emerging markets of South Africa, Kenya, and India. They needed to...

Conducting market research for scientific publication guide

Conducting and using market research for publication can be valuable for shaping opinions in healthcare. The findings can be used to influence existing perceptions, change current practices and behaviour in...

Therapy Watch appoints new Associate Director

Research Partnership has appointed Mark Hollis to join the Therapy Watch team as Associate Director. Mark has 8 years’ experience in syndicated healthcare, and previously worked in the Market Prognosis team at IQVIA...

Sabera Hyderally appointed Head of MedTech North America

Research Partnership is delighted to welcome Sabera Hyderally who has joined the company’s US headquarters in Philadelphia.